Dogwood Therapeutics, Inc.
NASDAQ:DWTXBiotechnology
+$0.04 today
- Market cap
- $51.12M
- Beta
- 1.76
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.84
Volume 0.12M
Average 0.09M
DWTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Dogwood Therapeutics, Inc.NASDAQ: DWTX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$5.08M, compared with -$4.43M a year earlier. Trailing-twelve-month operating income was -$28.61M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating income holds near -$5.08M or moves back toward the trailing-twelve-month quarterly average of -$7.15M.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (27.97M) USD
- Year-over-year change
- -128.7%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.97M) | -128.7% |
| FY2024 | 2024-12-31 | (12.23M) | -124.5% |
| FY2023 | 2023-12-31 | (5.45M) | +55.8% |
| FY2022 | 2022-12-31 | (12.32M) | +21.3% |
| FY2021 | 2021-12-31 | (15.64M) | — |
Operating Income vs competitors
How DWTX compares with its peers on the latest reported figures
- DWTX's LTM Mar 2026 operating income of -$28.61M is the lowest of the 2 companies compared; the peer median is -$11.01M.
- Its year-over-year change of -86.5% is the lowest of 2, against a peer median of -70.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$11.01M | -70.1% | — | — | |
| LTM Mar 2026 | -$28.61M | -86.5% | — | — | |
| Peer median (excluding DWTX) | -$11.01M | -70.1% | — | — | |
Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.8M | 8.07M | 1.73M | 3.53M | 21.87M |
| Selling, General & Admin | 4.85M | 4.25M | 3.72M | 8.7M | 6.1M |
| Operating Expenses | 15.64M | 12.32M | 5.45M | 12.23M | 27.97M |
| Depreciation & Amortization | 0 | 0 | 0 | 12.18K | 2.06K |
| EBITDA | (15.96M) | (12.25M) | (5.3M) | (12.25M) | (34.03M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.64M) | (12.32M) | (5.45M) | (12.23M) | (27.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5.67K | 67.48K | 150.9K | 0 | 96.94K |
| Interest Expense | 0 | 0 | 0 | 92.19K | 0 |
| Other Income / Expenses | (319.33K) | 67.48K | 150.9K | (122.98K) | (6.07M) |
| Income Before Tax | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | (503) | 221.1K |
| Net Income | (15.96M) | (12.25M) | (5.3M) | (12.35M) | (34.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| EPS (Diluted) | (47.90) | (27.66) | (7.05) | (12.52) | (4.32) |
| Weighted Avg Shares | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M |
| Weighted Avg Shares (Diluted) | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M |
Dogwood Therapeutics, Inc.
NASDAQ:DWTX
Intrinsic Alpha fair value
Locked
Current Price
$1.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.